The latest biotech news

News and Trends 20 May 2019

UK Immune Cell Therapy Biotech Founded with €40M Series A

Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases, launched today with €40M series A funding. UK life sciences trust Syncona is the lead investor, with a €38.8M stake in the company. Syncona will own a controlling 69% of the business, reflecting their large initial investment. […]

May 20, 2019 - 2 minutesmins - By Helen Albert

News and Trends 20 May 2019

Update: British RNA Biotech Increases Series A to €34M

Update (20/05/19): Storm Therapeutics has increased its series A financing round by an additional €16M (£14M) to €34M (£30M), which the company plans to use to advance its pipeline of RNA focused drug candidates towards the clinic. Seroba Life Sciences, an Irish VC focusing on new and innovative therapies, is the key new investor. Existing […]

May 20, 2019 - 2 minutesmins - By Helen Albert

mobidiag antibiotic resistance diagnostic

News and Trends 15 May 2019

€25M European Loan to Fund Diagnostics Tackling Antibiotic Resistance

The Finnish biotech Mobidiag has received a loan of €25M from the European Investment Bank to commercialize diagnostic technology aimed at reducing antibiotic resistance. When patients get a bacterial infection, clinicians have to wait several days for traditional diagnosis techniques to tell them what kind of bacteria is causing the infection. While they wait, the […]

May 15, 2019 - 2 minutesmins - By Jonathan Smith

celixir rnai silencing cancer colon breast

News and Trends 14 May 2019

RNAi Therapy Smashes Solid Tumors in Preclinical Tests

Developed by the UK biotech Celixir, a therapy based on silencing genes with RNA molecules in a process called RNAi has shrunk tumors by 50% in culture. Although there are lots of innovative cancer treatments in the market, such as CAR T-cell therapy for blood cancer, solid tumors remain difficult to tackle. For this reason, […]

May 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 14 May 2019

First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II

A gene therapy developed by the Dutch biotech uniQure increased the activity of a blood clotting protein enough to stop bleeds in patients with the blood disorder hemophilia B. Hemophilia B is a rare genetic condition in which patients have a mutation in the blood clotting protein factor IX (FIX), reducing its activity below 6% […]

May 14, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 13 May 2019

‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding

The Swiss-Italian biotech company Philogen has raised a private round of €62M to fund the phase III development of cancer immunotherapies that deliver immune cell-stimulating molecules directly to the tumor site. The money will push Philogen’s two lead cancer programs, currently in phase III, to the market. The funds will also help to expand the […]

May 13, 2019 - 2 minutesmins - By Jonathan Smith

treefrog therapeutics cell therapy parkinsons disease

News and Trends 13 May 2019

Cell Encapsulation Biotech Raises €7M to Target Cell Therapy Bottlenecks

The French company Treefrog Therapeutics has raised over €7M in Series A investment to develop its encapsulation technology to improve the production of stem cells for cell therapies. Part of the Series A money will help Treefrog to automate its stem cell production process by 2021. The round will also fund the development of a […]

May 13, 2019 - 3 minutesmins - By Jonathan Smith

pneumonia lungs polyphor antibiotic resistance

News and Trends 10 May 2019

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Polyphor has temporarily halted two phase III trials of an antibiotic treating pneumonia, after an unexpectedly high number of patients reported kidney problems in one of the trials. The phase III trial was testing the antibiotic murepavadin in 150 enrolled patients with hospital-acquired pneumonia, and who required mechanical breathing. The patients in the treatment group […]

May 10, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 8 May 2019

Schizophrenia Treatments Could be Tested and Personalized Using Patients’ Blood

Scientists at the University of Cambridge have developed a way to screen treatments for schizophrenia on single cells from a patient’s blood sample, which could speed up drug discovery and help to personalize treatments for people with the condition. Around 21 million people worldwide suffer from schizophrenia, and this is likely to get worse with […]

May 8, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 May 2019

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]

May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

bees dying university of Cambridge vaccine virus

News and Trends 6 May 2019

Molecules in Bee Jelly Could Protect Whole Nests Against Viruses for Generations

A research team has discovered that honeybees pass molecules of RNA to each other by sharing it in edible jelly, which could lead to vaccines that can stop generations of bees from dying from viral infections. Honeybees don’t just give us honey. As the dominant pollinators of lots of food crops, around a third of […]

May 6, 2019 - 2 minutesmins - By Jonathan Smith

combioxin antibiotic resistance pneumonia

News and Trends 3 May 2019

Drug Mopping Up Bacterial Toxins Shows Potential to Tackle Antibiotic Resistance in Phase I

An antibiotic-enhancing drug developed by the Swiss biotech Combioxin to tackle antibiotic resistance showed promising effects in a phase I trial. Antibiotic resistance is a growing problem around the world, causing common infections such as pneumonia to become harder to treat. As standard antibiotics become less and less effective, we urgently need to find new […]

May 3, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

UK Immune Cell Therapy Biotech Founded with €40M Series A

Update: British RNA Biotech Increases Series A to €34M

€25M European Loan to Fund Diagnostics Tackling Antibiotic Resistance

RNAi Therapy Smashes Solid Tumors in Preclinical Tests

First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II

‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding

Cell Encapsulation Biotech Raises €7M to Target Cell Therapy Bottlenecks

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Schizophrenia Treatments Could be Tested and Personalized Using Patients’ Blood

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

Molecules in Bee Jelly Could Protect Whole Nests Against Viruses for Generations

Drug Mopping Up Bacterial Toxins Shows Potential to Tackle Antibiotic Resistance in Phase I

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!